Patents by Inventor Ivan M. Nunez
Ivan M. Nunez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11897985Abstract: A water extractable ophthalmic device is disclosed which is a polymerization product of a monomeric mixture comprising: (a) one or more cyclic lactams; (b) one or more non-bulky organosilicon-containing monomers; (c) one or more bulky siloxane monomers; and (d) a crosslinking agent mixture comprising (i) one or more first crosslinking agents containing at least two ethylenically unsaturated reactive end groups, wherein the at least two ethylenically unsaturated reactive end groups are (meth)acrylate-containing reactive end groups and (ii) one or more second crosslinking agents containing at least two ethylenically unsaturated reactive end groups wherein at least one of the ethylenically unsaturated reactive end groups is a non-(meth)acrylate reactive end group. The water extractable ophthalmic device has an equilibrium water content of at least about 50 wt. %, a contact angle of less than about 50°, and an oxygen permeability of at least about 60 Barrers.Type: GrantFiled: April 26, 2022Date of Patent: February 13, 2024Assignee: Bausch & Lomb IncorporatedInventors: Ivan M. Nuñez, Lynn Coullard, Analuz Mark, Andrew J. Hoteling, Joseph W. Hoff
-
Patent number: 11702500Abstract: A biomedical device is disclosed which is a polymerization product of a mixture comprising (a) one or more difunctional isocyanates; (b) one or more polyalcohols; (c) one or more hydroxy-terminated polysiloxane prepolymers; and (d) one or more polyoxazoline polyols having a weight average molecular weight of equal to or greater than about 1000 Daltons.Type: GrantFiled: March 15, 2022Date of Patent: July 18, 2023Assignee: Bausch + Lomb Ireland LimitedInventors: Ivan M. Nuñez, Lynn Coullard, Katie L. Poetz
-
Patent number: 11492189Abstract: A packaging system for the storage of an ophthalmic device is disclosed. The packaging system comprises a sealed container containing one or more unused ophthalmic devices immersed in an aqueous packaging solution comprising one or more hydrophilic polymers or copolymers comprising hydrophilic units and endcapped with a hydrophobic end group and a hydrophilic end group, wherein the solution has an osmolality of at least about 200 mOsm/kg, a pH of about 6 to about 9 and is heat sterilized.Type: GrantFiled: January 28, 2020Date of Patent: November 8, 2022Assignee: Bausch & Lomb IncorporatedInventors: Analuz Mark, Ivan M. Nuñez, Vicki L. Barniak, Jennifer M. Hunt, Lynn Coullard, Keyla M. Cubi
-
Publication number: 20220298287Abstract: A biomedical device is disclosed which is a polymerization product of a mixture comprising (a) one or more difunctional isocyanates; (b) one or more polyalcohols; (c) one or more hydroxy-terminated polysiloxane prepolymers; and (d) one or more polyoxazoline polyols having a weight average molecular weight of equal to or greater than about 1000 Daltons.Type: ApplicationFiled: March 15, 2022Publication date: September 22, 2022Inventors: Ivan M. Nuñez, Lynn Coullard, Katie L. Poetz
-
Publication number: 20220288270Abstract: A packaging system for the storage of an ophthalmic device is disclosed. The packaging system includes a sealed container containing one or more unused ophthalmic devices immersed in an aqueous packaging solution that includes one or more conjugated glycosaminoglycans having a polymer backbone having a reactive functional moiety conjugated to an amine group having one or more moieties that inhibit and/or prevent one or more of oxidation and hydrolytic degradation of the polymer backbone during use in the eye; wherein the aqueous packaging solution has an osmolality of at least about 150 mOsm/kg, a pH of about 6 to about 9 and is sterilized.Type: ApplicationFiled: March 8, 2022Publication date: September 15, 2022Inventors: Katie L. Poetz, Ivan M. Nuñez, Analuz Mark, Grace Bennett, Robert Steffen, Andrew J. Hoteling, Michelle Piotrowski, Brendan Shannon, Keyla Cubi, Alana Ingham
-
Publication number: 20220251269Abstract: A water extractable ophthalmic device is disclosed which is a polymerization product of a monomeric mixture comprising: (a) one or more cyclic lactams; (b) one or more non-bulky organosilicon-containing monomers; (c) one or more bulky siloxane monomers; and (d) a crosslinking agent mixture comprising (i) one or more first crosslinking agents containing at least two ethylenically unsaturated reactive end groups, wherein the at least two ethylenically unsaturated reactive end groups are (meth)acrylate-containing reactive end groups and (ii) one or more second crosslinking agents containing at least two ethylenically unsaturated reactive end groups wherein at least one of the ethylenically unsaturated reactive end groups is a non-(meth)acrylate reactive end group. The water extractable ophthalmic device has an equilibrium water content of at least about 50 wt. %, a contact angle of less than about 50°, and an oxygen permeability of at least about 60 Barrers.Type: ApplicationFiled: April 26, 2022Publication date: August 11, 2022Inventors: Ivan M. Nuñez, Lynn Coullard, Analuz Mark, Andrew J. Hoteling, Joseph W. Hoff
-
Patent number: 11345773Abstract: A water extractable ophthalmic device is disclosed which is a polymerization product of a monomeric mixture comprising: (a) one or more cyclic lactams; (b) one or more non-bulky organosilicon-containing monomers; (c) one or more bulky siloxane monomers; and (d) a crosslinking agent mixture comprising (i) one or more first crosslinking agents containing at least two ethylenically unsaturated reactive end groups, wherein the at least two ethylenically unsaturated reactive end groups are (meth)acrylate-containing reactive end groups and (ii) one or more second crosslinking agents containing at least two ethylenically unsaturated reactive end groups wherein at least one of the ethylenically unsaturated reactive end groups is a non-(meth)acrylate reactive end group. The water extractable ophthalmic device has an equilibrium water content of at least about 50 wt. %, a contact angle of less than about 50°, and an oxygen permeability of at least about 60 Barrers.Type: GrantFiled: April 5, 2019Date of Patent: May 31, 2022Assignee: Bausch & Lomb IncorporatedInventors: Ivan M. Nuñez, Lynn Coullard, Analuz Mark, Andrew J. Hoteling, Joseph W. Hoff
-
Patent number: 11022722Abstract: A water extractable ophthalmic device is disclosed which is a polymerization product of a monomeric mixture comprising: (a) one or more cyclic lactams; (b) one or more organosilicon-containing block copolymers; (c) one or more bulky siloxane monomers; and (d) a crosslinking agent mixture comprising (i) one or more first crosslinking agents containing at least two ethylenically unsaturated reactive end groups, wherein the at least two ethylenically unsaturated reactive end groups are (meth)acrylate-containing reactive end groups and (ii) one or more second crosslinking agents containing at least two ethylenically unsaturated reactive end groups wherein at least one of the ethylenically unsaturated reactive end groups is a non-(meth)acrylate reactive end group. The water extractable ophthalmic device has an equilibrium water content of at least about 50 wt. %, a contact angle of less than about 50°, and an oxygen permeability of at least about 60 Barrers.Type: GrantFiled: May 17, 2019Date of Patent: June 1, 2021Assignee: Bausch & Lomb IncorporatedInventors: Ivan M. Nuñez, Katie L. Poetz, Lynn Coullard, Alok Kumar Awasthi, Analuz Mark, Joseph W. Hoff, Andrew J. Hoteling
-
Patent number: 10870731Abstract: A method is disclosed which involves the steps of (a) reacting a polysiloxane prepolymer having reactive functional end groups with a non-free radical polymerizable reactive end-capping agent; and (b) reacting the reaction product of step (a) with a free radical polymerizable reactive end-capping agent.Type: GrantFiled: January 14, 2019Date of Patent: December 22, 2020Assignee: Bausch & Lomb IncorporatedInventors: Ivan M. Nuñez, Katie L. Poetz, Andrew J. Hoteling, Joseph W. Hoff, Lynn Coullard, Analuz Mark, Keyla M. Cubi, Joseph A. McGee
-
Patent number: 10816698Abstract: An ophthalmic device is disclosed which is a polymerization product of a monomeric mixture comprising: (a) a major amount of one or more first non-silicone-containing hydrophilic monomers; (b) one or more hydrophobic monomers; and (c) a crosslinking agent mixture comprising (i) one or more di-, tri- or tetra(meth)acrylate-containing crosslinking agents and (ii) one or more di-, tri- or tetracarbamate-containing crosslinking agents, wherein the ophthalmic device has an equilibrium water content of at least about 65 weight percent.Type: GrantFiled: August 10, 2018Date of Patent: October 27, 2020Assignee: Bausch & Lomb IncorporatedInventors: Ivan M. Nuñez, Katie L. Poetz, Joseph W. Hoff, Judith Chapman Morgan
-
Publication number: 20200239217Abstract: A packaging system for the storage of an ophthalmic device is disclosed. The packaging system comprises a sealed container containing one or more unused ophthalmic devices immersed in an aqueous packaging solution comprising one or more hydrophilic polymers or copolymers comprising hydrophilic units and endcapped with a hydrophobic end group and a hydrophilic end group, wherein the solution has an osmolality of at least about 200 mOsm/kg, a pH of about 6 to about 9 and is heat sterilized.Type: ApplicationFiled: January 28, 2020Publication date: July 30, 2020Inventors: Analuz Mark, Ivan M. Nuñez, Vicki L. Barniak, Jennifer M. Hunt, Lynn Coullard, Keyla M. Cubi
-
Patent number: 10668676Abstract: An ophthalmic device is disclosed that is a polymerization product of a monomeric mixture comprising: (a) a major amount of one or more non-silicone-containing hydrophilic monomers; (b) a crosslinking agent mixture comprising (i) one or more first crosslinking agents containing at least two ethylenically unsaturated reactive end groups, wherein the at least two ethylenically unsaturated reactive end groups are (meth)acrylate-containing reactive end groups and (ii) one or more second crosslinking agents containing at least two ethylenically unsaturated reactive end groups wherein at least one of the ethylenically unsaturated reactive end groups is a non-(meth)acrylate reactive end group, and (c) one or more hydrophilic polymers or copolymers comprising one or more hydrophilic units and a thio carbonyl thio fragment of a reversible addition fragmentation chain transfer (“RAFT”) agent wherein the ophthalmic device has an equilibrium water content of at least about 45 weight percent.Type: GrantFiled: August 10, 2018Date of Patent: June 2, 2020Assignee: Bausch & Lomb IncorporatedInventors: Ivan M. Nuñez, Lynn Coullard, Daniel J. Hook, Robert B. Steffen, Daniel M. Ammon, Jennifer M. Hunt, Analuz Mark
-
Publication number: 20200047437Abstract: An ophthalmic device is disclosed that is a polymerization product of a monomeric mixture comprising: (a) a major amount of one or more non-silicone-containing hydrophilic monomers; (b) a crosslinking agent mixture comprising (i) one or more first crosslinking agents containing at least two ethylenically unsaturated reactive end groups, wherein the at least two ethylenically unsaturated reactive end groups are (meth)acrylate-containing reactive end groups and (ii) one or more second crosslinking agents containing at least two ethylenically unsaturated reactive end groups wherein at least one of the ethylenically unsaturated reactive end groups is a non-(meth)acrylate reactive end group, and (c) one or more hydrophilic polymers or copolymers comprising one or more hydrophilic units and a thio carbonyl thio fragment of a reversible addition fragmentation chain transfer (“RAFT”) agent wherein the ophthalmic device has an equilibrium water content of at least about 45 weight percent.Type: ApplicationFiled: August 10, 2018Publication date: February 13, 2020Inventors: Ivan M. Nuñez, Lynn Coullard, Daniel J. Hook, Robert B. Steffen, Daniel M. Ammon, Jennifer M. Hunt, Analuz Mark
-
Publication number: 20200049857Abstract: An ophthalmic device is disclosed which is a polymerization product of a monomeric mixture comprising: (a) a major amount of one or more first non-silicone-containing hydrophilic monomers; (b) one or more hydrophobic monomers; and (c) a crosslinking agent mixture comprising (i) one or more di-, tri- or tetra(meth)acrylate-containing crosslinking agents and (ii) one or more di-, tri- or tetracarbamate-containing crosslinking agents, wherein the ophthalmic device has an equilibrium water content of at least about 65 weight percent.Type: ApplicationFiled: August 10, 2018Publication date: February 13, 2020Inventors: Ivan M. Nuñez, Katie L. Poetz, Joseph W. Hoff, Judith Chapman Morgan
-
Publication number: 20200012015Abstract: A water extractable ophthalmic device is disclosed which is a polymerization product of a monomeric mixture comprising: (a) one or more cyclic lactams; (b) one or more organosilicon-containing block copolymers; (c) one or more bulky siloxane monomers; and (d) a crosslinking agent mixture comprising (i) one or more first crosslinking agents containing at least two ethylenically unsaturated reactive end groups, wherein the at least two ethylenically unsaturated reactive end groups are (meth)acrylate-containing reactive end groups and (ii) one or more second crosslinking agents containing at least two ethylenically unsaturated reactive end groups wherein at least one of the ethylenically unsaturated reactive end groups is a non-(meth)acrylate reactive end group. The water extractable ophthalmic device has an equilibrium water content of at least about 50 wt. %, a contact angle of less than about 50°, and an oxygen permeability of at least about 60 Barrers.Type: ApplicationFiled: May 17, 2019Publication date: January 9, 2020Inventors: Ivan M. Nuñez, Katie L. Poetz, Lynn Coullard, Alok Kumar Awasfhi, Analuz Mark, Joseph W. Hoff, Andrew J. Hoteling
-
Publication number: 20190352443Abstract: A water extractable ophthalmic device is disclosed which is a polymerization product of a monomeric mixture comprising: (a) one or more cyclic lactams; (b) one or more non-bulky organosilicon-containing monomers; (c) one or more bulky siloxane monomers; and (d) a crosslinking agent mixture comprising (i) one or more first crosslinking agents containing at least two ethylenically unsaturated reactive end groups, wherein the at least two ethylenically unsaturated reactive end groups are (meth)acrylate-containing reactive end groups and (ii) one or more second crosslinking agents containing at least two ethylenically unsaturated reactive end groups wherein at least one of the ethylenically unsaturated reactive end groups is a non-(meth)acrylate reactive end group. The water extractable ophthalmic device has an equilibrium water content of at least about 50 wt. %, a contact angle of less than about 50°, and an oxygen permeability of at least about 60 Barrers.Type: ApplicationFiled: April 5, 2019Publication date: November 21, 2019Inventors: Ivan M. Nuñez, Lynn Coullard, Analuz Mark, Andrew J. Hoteling, Joseph W. Hoff
-
Publication number: 20190233593Abstract: A method is disclosed which involves the steps of (a) reacting a polysiloxane prepolymer having reactive functional end groups with a non-free radical polymerizable reactive end-capping agent; and (b) reacting the reaction product of step (a) with a free radical polymerizable reactive end-capping agent.Type: ApplicationFiled: January 14, 2019Publication date: August 1, 2019Inventors: Ivan M. Nuñez, Katie L. Poetz, Andrew J. Hoteling, Joseph W. Hoff, Lynn Coullard, Analuz Mark, Keyla M. Cubi, Joseph A. McGee
-
Patent number: 9285508Abstract: Biomedical devices such as contact lenses formed from a polymerization product of a mixture comprising (a) a multi-armed macromonomer comprising multiple side chains attached to a nucleus, wherein each side chain comprises a thio carbonyl thio fragment of the same or different reversible addition fragmentation chain transfer (“RAFT”) agent; and (b) one or more biomedical device-forming monomers are disclosed.Type: GrantFiled: June 16, 2009Date of Patent: March 15, 2016Assignee: Bausch & Lomb IncorporatedInventors: Ivan M. Nunez, Jay F. Kunzler, Jeffrey G. Linhardt, Jennifer Hunt
-
Patent number: 9075187Abstract: A substantially fully copolymerized UV blocking hydrogel lens demonstrating sufficient blocking of UV light to meet at least FDA Class II specifications for UV blocking formed from a reaction mixture comprising at least NVP and one other comonomer and a free-radical polymerizable, substituted or unsubstituted, Bis O-hydroxy benzophenone is provided herein.Type: GrantFiled: December 20, 2012Date of Patent: July 7, 2015Assignee: Bausch & Lomb IncorporatedInventors: Ivan M. Nunez, Jennifer Hunt
-
Patent number: 8967799Abstract: A method of preparing a water extractable silicon-containing biomedical device is disclosed. The method involves curing a monomer mixture comprising one or more silicon-containing biomedical device-forming monomers in the presence of a diluent to produce a silicon-containing biomedical device; wherein the diluent comprises a boric acid ester of a C1 to C8 monohydric alcohol.Type: GrantFiled: December 20, 2012Date of Patent: March 3, 2015Assignee: Bausch & Lomb IncorporatedInventors: Ivan M. Nunez, Joseph A. McGee, Jay Friedrich Kunzler, Michele Alton, Analuz Changano, Jennifer Hunt